Colleen T. Harrington
Neuroscience · The Ohio State University
Publications
33
Citations
1,881
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2009
This researcher's publication record spans multiple distinct areas, including immune interactions with oligodendrocytes (the cells that produce myelin) in multiple sclerosis models, drug-screening platforms for cancer therapeutics, CAR-T cell immunotherapy resistance mechanisms, and clinical neurology topics such as care for transgender patients and rare neuroimmunological disorders. The mix of topics and venues suggests contributions across several collaborative projects rather than a single narrow research program. Prospective students should note that the bibliographic record reflects work at the intersection of neuroimmunology, cancer biology, and clinical neurology.
Publication output was minimal or absent in several years earlier in the decade but increased notably from 2023 onward, suggesting a recent rise in publishing activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 2930: Unraveling determinants of drug response: PRISM viability profiling of hundreds of oncology therapeutics reveals mediators of selectivity and mechanism.
Cancer Research · 2026
- Abstract 4502: Expanding the PRISM platform: Addition of new hematologic models and a 10-day assay improve drug sensitivity mapping for epigenetic targets.
Cancer Research · 2026
- Linker for activation of T cells (LAT) mutation leading to CNS neuroimmunological disorder with treatment response to abatacept
Neuroimmunology Reports · 2025
- Abstract 6763: A cellular platform for systematic comparison of RAS inhibitors using PRISM multiplexed screening
Cancer Research · 2025
- Oligodendrocyte progenitor cell responses to inflammatory demyelination with aging in mouse model of multiple sclerosis
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract A026: Defining the epigenetic drug landscape and rational combinations for pediatric cancer using the PRISM screening assay
Cancer Research · 2025
- Advancing LGBTQI+ Equity in Neurology
Neurology · 2024
- Neurologic Care for Transgender and Gender-Diverse People
Neurology Clinical Practice · 2024
- Acute onset of autoimmune hepatitis after initiation of B cell depletion therapy in multiple sclerosis
Neuroimmunology Reports · 2024
- MHC class I and MHC class II reporter mice enable analysis of immune oligodendroglia in mouse models of multiple sclerosis
eLife · 2023
- Remyelination in animal models of multiple sclerosis: finding the elusive grail of regeneration
Frontiers in Molecular Neuroscience · 2023
- Supplementary Tables 1 - 9 from Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy
2023
- Supplementary Figures 1 - 2 from Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy
2023
- Supplementary Figures 1 - 2 from Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy
2023
- Supplementary Tables 1 - 9 from Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy
2023
- Cancer Research×4
- Leukemia×2
- Neuroimmunology Reports×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- American Journal of Hematology×1
- Ranjie Xu
Neuroscience · Purdue University West Lafayette
- Kyle Wettschurack
Neuroscience · Purdue University West Lafayette
- Kaushik Sharma
Neuroscience · Purdue University West Lafayette
- Season K. Wyatt‐Johnson
Neuroscience · Indiana University
- Barbara A. Scofield
Neuroscience · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile